Editorial for Cancer Virtual Issue

Overview

Journal ACS Med Chem Lett

Publisher American Chemical Society

Specialty Chemistry

Date 2017 Dec 21

PMID 29259733

Authors

Benjamin E Blass

Affiliations

Soon will be listed here.

References

Ignoffo R . Capecitabine: A new oral fluoropyrimidine. Cancer Pract. 1998; 6(5):302-4. DOI: 10.1046/j.1523-5394.1998.00028.x. View

Weisberg E, Manley P, Mestan J, Cowan-Jacob S, Ray A, Griffin J . AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Cancer. 2006; 94(12):1765-9. PMC: 2361347. DOI: 10.1038/sj.bjc.6603170. View

Bertino E, Otterson G . Romidepsin: a novel histone deacetylase inhibitor for cancer. Expert Opin Investig Drugs. 2011; 20(8):1151-8. DOI: 10.1517/13543784.2011.594437. View

Signorelli J, Shah Gandhi A . Cobimetinib. Ann Pharmacother. 2016; 51(2):146-153. DOI: 10.1177/1060028016672037. View

Richon V, Zhou X, Rifkind R, Marks P . Histone deacetylase inhibitors: development of suberoylanilide hydroxamic acid (SAHA) for the treatment of cancers. Blood Cells Mol Dis. 2001; 27(1):260-4. DOI: 10.1006/bcmd.2000.0376. View

Aoude L, Wadt K, Pritchard A, Hayward N . Genetics of familial melanoma: 20 years after CDKN2A. Pigment Cell Melanoma Res. 2014; 28(2):148-60. DOI: 10.1111/pcmr.12333. View

Zain J, OConnor O . Pralatrexate: basic understanding and clinical development. Expert Opin Pharmacother. 2010; 11(10):1705-14. DOI: 10.1517/14656566.2010.489552. View

Marsh J, DeConti R, Hubbard S . Treatment of Hodgkin's disease and other cancers with 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962). Cancer Chemother Rep. 1971; 55(5):599-606. View

Masuda N, Kudoh S, Fukuoka M . Irinotecan (CPT-11): pharmacology and clinical applications. Crit Rev Oncol Hematol. 1996; 24(1):3-26. DOI: 10.1016/1040-8428(96)00201-6. View

10.

Hanahan D, Weinberg R . The hallmarks of cancer. Cell. 2000; 100(1):57-70. DOI: 10.1016/s0092-8674(00)81683-9. View

11.

Bouchet B, Galmarini C . Cabazitaxel, a new taxane with favorable properties. Drugs Today (Barc). 2010; 46(10):735-42. DOI: 10.1358/dot.2010.46.10.1519019. View

12.

Gilman A . The initial clinical trial of nitrogen mustard. Am J Surg. 1963; 105:574-8. DOI: 10.1016/0002-9610(63)90232-0. View

13.

Carter S, Livingston R . Cyclophosphamide in solid tumors. Cancer Treat Rev. 1975; 2(4):295-322. DOI: 10.1016/s0305-7372(75)80010-7. View

14.

Farber S, DIAMOND L . Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid. N Engl J Med. 1948; 238(23):787-93. DOI: 10.1056/NEJM194806032382301. View

15.

Lindor N, McMaster M, Lindor C, Greene M . Concise handbook of familial cancer susceptibility syndromes - second edition. J Natl Cancer Inst Monogr. 2008; (38):1-93. DOI: 10.1093/jncimonographs/lgn001. View

16.

Atadja P . Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges. Cancer Lett. 2009; 280(2):233-41. DOI: 10.1016/j.canlet.2009.02.019. View

17.

Witterland A, Koks C, Beijnen J . Etoposide phosphate, the water soluble prodrug of etoposide. Pharm World Sci. 1996; 18(5):163-70. DOI: 10.1007/BF00820727. View

18.

Garcia-Sanz R . Thalidomide in multiple myeloma. Expert Opin Pharmacother. 2006; 7(2):195-213. DOI: 10.1517/14656566.7.2.195. View

19.

Guchelaar H, Richel D, van Knapen A . Clinical, toxicological and pharmacological aspects of gemcitabine. Cancer Treat Rev. 1996; 22(1):15-31. DOI: 10.1016/s0305-7372(96)90014-6. View

20.

Fornier M . Ixabepilone, first in a new class of antineoplastic agents: the natural epothilones and their analogues. Clin Breast Cancer. 2007; 7(10):757-63. View